Business Wire

Global Progressive Supranuclear Palsy Treatment Market to Surpass US$ 20.68 Million by 2027, Says Coherent Market Insights (CMI)

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global progressive supranuclear palsy treatment market is estimated to be valued at US$ 14.38 million in 2020 and is expected to ...
FOX8 Cleveland

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy Clinical Trial at Neuro2024

- Topline supports moving to Phase 3 trial and shows potential to develop GV1001 as the world's first PSP treatment PSP is a degenerative disease that, like Parkinson's disease, causes symptoms ...
Digital Journal

Progressive Supranuclear Palsy Treatment market with upcoming trends, technology, innovations, and forecast by 2029

The market size of the progressive supranuclear palsy treatment market is expected to experience significant growth in the coming years, as more research is conducted on the disease and new ...
The Victoria Advocate

Seoul National University Bundang Hospital Establishes the first "International PSP Research and Treatment Center" in Korea

The International PSP Research and Treatment Center (the "Center") will integrate the infrastructure and expertise of the three parties to execute a comprehensive array of functions, including ...
아시아경제

GemVax, Bundang Seoul National University Hospital, and CurePSP Establish International PSP

GemVax & Kael announced on the 6th that it will establish the 'International Progressive Supranuclear Palsy (PSP) Treatment Center' together with Bundang Seoul National University Hospital and ...
News Medical

C2N-8E12 (ABBV-8E12) gets orphan drug designation from FDA for PSP treatment

C 2 N Diagnostics and AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has granted their investigational recombinant humanized anti-tau antibody, C 2 N-8E12 ...